Crescent Biopharma, Inc. (CBIO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 17.69 |
| Open | 18.26 |
| Day High | 18.73 |
| Day Low | 17.5 |
| 52-Week High | 27.41 |
| 52-Week Low | 8.72 |
| Volume | 305,470 |
| Average Volume | 279,638 |
| Market Cap | 484.44M |
| PE | -2.99 |
| EPS | -5.88 |
| Moving Average 50 Days | 19.79 |
| Moving Average 200 Days | 14.31 |
| Change | -0.12 |
Crescent Biopharma to Present at March Investor Conferences
GlobeNewswire Inc.
Feb 23, 2026 12:30 PM GMT
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today ann
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
GlobeNewswire Inc.
Feb 18, 2026 12:30 PM GMT
ASCEND to evaluate CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types, including NSCLC and gastrointestinal and gynecological cancers in first-line and previously treated patients Company anticipates reporting proof-of-concept d
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 12:30 PM GMT
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today ann